USD 0.03
(6.67%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 7.16 Million USD | -56.22% |
2022 | 16.36 Million USD | -5.21% |
2021 | 17.26 Million USD | 103.96% |
2020 | 8.46 Million USD | 198.45% |
2019 | 2.83 Million USD | 30.93% |
2018 | 2.16 Million USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 4.12 Million USD | 13.85% |
2024 Q1 | 3.62 Million USD | 148.13% |
2023 Q1 | 4.17 Million USD | -15.96% |
2023 FY | 7.16 Million USD | -56.22% |
2023 Q3 | 5.23 Million USD | -0.96% |
2023 Q2 | 5.28 Million USD | 26.83% |
2023 Q4 | -7.53 Million USD | -243.8% |
2022 Q3 | 3.64 Million USD | -10.6% |
2022 Q2 | 4.07 Million USD | 10.73% |
2022 Q1 | 3.68 Million USD | -15.61% |
2022 FY | 16.36 Million USD | -5.21% |
2022 Q4 | 4.96 Million USD | 36.17% |
2021 FY | 17.26 Million USD | 103.96% |
2021 Q3 | 4.6 Million USD | -2.29% |
2021 Q4 | 4.36 Million USD | -5.19% |
2021 Q2 | 4.7 Million USD | 31.13% |
2021 Q1 | 3.59 Million USD | 39.51% |
2020 Q3 | 3.17 Million USD | 179.81% |
2020 Q2 | 1.13 Million USD | -28.36% |
2020 Q1 | 1.58 Million USD | 136.62% |
2020 FY | 8.46 Million USD | 198.45% |
2020 Q4 | 2.57 Million USD | -18.88% |
2019 Q1 | 787 Thousand USD | 0.0% |
2019 FY | 2.83 Million USD | 30.93% |
2019 Q4 | 669 Thousand USD | 3.56% |
2019 Q3 | 646 Thousand USD | -11.99% |
2019 Q2 | 734 Thousand USD | -6.73% |
2018 FY | 2.16 Million USD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Biotricity, Inc. | 12.06 Million USD | 40.613% |
Cell MedX Corp. | - USD | -Infinity% |
Dynatronics Corporation | 32.53 Million USD | 77.98% |
Nemaura Medical Inc. | 77.04 Thousand USD | -9198.583% |
PetVivo Holdings, Inc. | 968.7 Thousand USD | -639.543% |
RetinalGenix Technologies Inc. | - USD | -Infinity% |
Sonendo, Inc. | 43.86 Million USD | 83.668% |
Telesis Bio, Inc. | 27.5 Million USD | 73.958% |
Talis Biomedical Corporation | 412 Thousand USD | -1638.835% |
Viveve Medical, Inc. | 6.42 Million USD | -11.485% |